Can a cannabis compound calm autism irritability? new trial seeks answers

NCT ID NCT03202303

Recruiting now Symptom relief Sponsor: Montefiore Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether cannabidivarin (CBDV), a compound from cannabis, can reduce irritability and repetitive behaviors in children with autism spectrum disorder. About 100 children aged 5 to 18 will receive either CBDV or a placebo daily for several weeks. Researchers will track changes in behavior using parent-reported questionnaires.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cannabidivarin (CBDV)
What this could lead to: If it works, this could offer a new option to reduce irritability and repetitive behaviors in children with autism.
What could go wrong: This is an early Phase 2 trial with only 100 participants, so results may not apply to everyone. CBDV may cause side effects or prove no better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTISM SPECTRUM DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autism autism spectrum disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTISM SPECTRUM DISORDER

Contacts and locations

Locations

Montefiore Medical Center
RECRUITING

The Bronx, New York, 10467, United States
New York University (NYU) Langone
COMPLETED

New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.